|
| | Idarubicin Basic information |
| Product Name: | Idarubicin | | Synonyms: | 11-trihydroxy-(7s-cis)-alpha-l-lyxo-hexopyranosyl)oxy)-;4-demethoxy-daunomyci;4-demethoxydaunomycin;4-demethoxydaunorubicin;4-Demethoxy-daunorubicin;7,8,9,10-tetrahydro-9-acetyl-7-((3-amino-2,3,6-trideoxy-12-naphthacenedione;nsc-256439;(7S)-9-Acetyl-7β-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9β,11-trihydroxy-5,12-naphthacenedione | | CAS: | 58957-92-9 | | MF: | C26H27NO9 | | MW: | 497.49 | | EINECS: | 1806241-263-5 | | Product Categories: | Active Pharmaceutical Ingredients | | Mol File: | 58957-92-9.mol |  |
| | Idarubicin Chemical Properties |
| Boiling point | 589.46°C (rough estimate) | | density | 1.3477 (rough estimate) | | refractive index | 1.6000 (estimate) | | storage temp. | Keep in dark place,Sealed in dry,2-8°C | | form | solid | | pka | pKa 4.73± 0.21 (Uncertain) |
| Hazard Codes | T+ | | Risk Statements | 60-61-28-40 | | Safety Statements | 53-45 | | RIDADR | UN 2811 6.1/PG 2 | | WGK Germany | 3 | | RTECS | HB7877000 |
| | Idarubicin Usage And Synthesis |
| Uses | Antineoplastic. | | Indications | Idarubicin (Idamycin) differs from its parent compound,
daunorubicin, by the absence of the methoxy
group in the anthracycline ring structure. Its mechanisms
of action and resistance are similar to those of
doxorubicin and daunorubicin; however, it is more
lipophilic and more potent than these other anthracyclines.
Idarubicin undergoes extensive hepatic metabolism
and biliary excretion. Adverse reactions of idarubicin
are similar to those of its congeners. | | Definition | ChEBI: Idarubicin is a monosaccharide derivative, an anthracycline antibiotic and a deoxy hexoside. It derives from a hydride of a tetracene. |
| | Idarubicin Preparation Products And Raw materials |
|
